TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02102464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Description: The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Description: The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Study: NCT02404493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram Skin Barrier Emulsion
Description: EpiCeram Skin Barrier Emulsion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Colloidal Oatmeal Balm
Description: Experimental Product 1% Colloidal Oatmeal Balm
Study: NCT03435601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).
Study: NCT01611818

Intervention type: OTHER
Group type: OTHER
Intervention: Low Intensity Internet-delivered psychotherapy
Description: Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study

Intervention type: OTHER
Group type: OTHER
Intervention: Self-guided Internet delivered psychotherapy
Description: No contact with the therapists over the treatment period will be done.

Intervention type: OTHER
Group type: OTHER
Intervention: Improved treatment as usual
Description: Any kind of treatment administered by the GP to the patient with depression
Study: NCT01487304

Intervention type: DRUG
Intervention: Marketed low dose hormone replacement therapy
Description: A low dose of marketed HRT products prescribed at the discretion of the treating physician
Study: NCT03463434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Low Pressure-LAL
Description: Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
Study: NCT01175564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, single dose and 6 days repeated dose
Study: NCT03553849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low calorie diet
Description: The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
Study: NCT03385369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Single dose of MEDI0382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study: NCT03255252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
Study: NCT04621162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectations (initial)
Description: A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Expectations (initial)
Description: A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Expectations (initial)
Description: This group will act as a control. No expectations will be given that will influence the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectations (during intervention)
Description: A positive expectation will be given during the performance of the mental practice. This is working very well

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Negative Expectations (during intervention)
Description: A negative expectation will be given during the performance of the mental practice. This is working very bad

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Expectations (during intervention)
Description: This group will act as a control. No expectations will be given that will influence the participant.
Study: NCT02799173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RANKL/OPG ratio

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone densitometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fan beam CT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Study: NCT03337035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal oxytocin
Description: 4-24 IU per day, dosage gradually increases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal oxytocin
Description: 4-24 IU per day, dosage gradually increases

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral probiotics
Description: 200 million cfu per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: 2 pills per day
Study: NCT00494221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD2171
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD2171
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cediranib
Description: oral tablet
Study: NCT02563691

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT.
Study: NCT03973255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Posturography, Whole body vibration
Study: NCT02477449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: istaroxime
Description: 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: istaroxime
Description: 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: istaroxime
Description: 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9% Saline (NS)
Description: infusion for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9% Saline (NS)
Description: infusion for 24 hours
Study: NCT04267471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
Study: NCT02036255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurolidine Urokinase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurolidine Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurolidine Heparin
Study: NCT03544229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 maleate capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 maleate capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 maleate capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-906 maleate placebo-matching capsules.
Study: NCT03361098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg oral tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo exenatide
Description: placebo b.i.d. exenatide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo exenatide
Description: placebo b.i.d. exenatide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo dapagliflozin
Description: placebo tablets dapagliflozin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo dapagliflozin
Description: placebo tablets dapagliflozin
Study: NCT03623477

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation (CRT)
Description: Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT+ Social Cognition Training
Description: Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
Study: NCT02005068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
Study: NCT02650986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Description: Given IV
Study: NCT03228342

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MusculoSkeletal Ultrasound
Description: Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MusculoSkeletal Ultrasound
Description: Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.
Study: NCT05629247

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Systematic screening of immune deficiency
Description: Systematic screening of immune deficiency with blood tests
Study: NCT04185987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leone slide low friction elastomeric ligature
Description: Leone slide low friction elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leone slide low friction elastomeric ligature
Description: Leone slide low friction elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leone slide low friction elastomeric ligature
Description: Leone slide low friction elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leone slide low friction elastomeric ligature
Description: Leone slide low friction elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMO tough - o energy elastomeric ligature
Description: RMO tough - o energy elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMO tough - o energy elastomeric ligature
Description: RMO tough - o energy elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMO tough - o energy elastomeric ligature
Description: RMO tough - o energy elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMO tough - o energy elastomeric ligature
Description: RMO tough - o energy elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentsply sili tie elastomeric ligature
Description: Dentsply sili tie elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentsply sili tie elastomeric ligature
Description: Dentsply sili tie elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentsply sili tie elastomeric ligature
Description: Dentsply sili tie elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentsply sili tie elastomeric ligature
Description: Dentsply sili tie elastomeric ligature application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AO twisted ended ligature wire
Description: AO twisted ended ligature wire application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AO twisted ended ligature wire
Description: AO twisted ended ligature wire application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AO twisted ended ligature wire
Description: AO twisted ended ligature wire application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AO twisted ended ligature wire
Description: AO twisted ended ligature wire application
Study: NCT03187353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: The placebo capsule will be filled with microcellulose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: The placebo capsule will be filled with microcellulose.
Study: NCT03478046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
Study: NCT01664923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg, daily, by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg, daily, by mouth
Study: NCT02740361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis, DeprexisPlus
Description: Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis, DeprexisPlus
Description: Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
Study: NCT01940406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation procedure
Description: Device
Study: NCT00251056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 120mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 40 mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 240mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 400mg BD
Study: NCT03082612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-Based African American Cancer Survivorship Storytelling Intervention
Description: The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-Based African American Cancer Survivorship Storytelling Intervention
Description: The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research